https://scholars.lib.ntu.edu.tw/handle/123456789/536450
標題: | The New CHEST Guidelines on Antithrombotic Therapy for Atrial Fibrillation Should Consider Recent Data on Rivaroxaban | 作者: | Kim Y.-H. Shim J. CHIA-TI TSAI Wang C.-C. Vilela G. Muengtaweepongsa S. Kurniawan M. Maskon O. Hsu L.F. Nguyen T.H. Sim K. Camm A.J. |
公開日期: | 2019 | 出版社: | Elsevier Inc | 卷: | 155 | 期: | 6 | 起(迄)頁: | 1309-1311 | 來源出版物: | Chest | URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066016618&doi=10.1016%2fj.chest.2019.03.036&partnerID=40&md5=7b08688da2cb1c834342bc8fea0134f5 https://scholars.lib.ntu.edu.tw/handle/123456789/536450 |
ISSN: | 0012-3692 | DOI: | 10.1016/j.chest.2019.03.036 | SDG/關鍵字: | anticoagulant agent; antivitamin K; apixaban; dabigatran; edoxaban; rivaroxaban; warfarin; anticoagulant agent; fibrinolytic agent; warfarin; anticoagulant therapy; Asian; atrial fibrillation; bleeding; cerebrovascular accident; drug efficacy; drug safety; evidence based medicine; human; Letter; meta analysis (topic); phase 3 clinical trial (topic); practice guideline; priority journal; Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Rivaroxaban; Warfarin |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。